[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607904":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":39,"responsibleParty":93,"collaborators":95,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":24,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":24,"enrollmentInfo":110,"targetDuration":24,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"University Hospital Ostrava","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Primary Surgery","EXPERIMENTAL","Procedure: rectal resection with TME (Total Mesorectal Excision)",[13],"Procedure: Primary Surgery",{"label":15,"type":10,"description":16,"interventionNames":17},"Neoadjuvant radiochemotherapy and surgery","Procedure: rectal resection with TME performed 6-10 weeks after completion of chemoradiotherapy.",[18],"Procedure: Neoadjuvant radiochemotherapy and surgery",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Patients undergo radical surgical resection with TME without preceding neoadjuvant therapy",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Neoadjuvant treatment: long-course pelvic radiotherapy (conventional fractionation) with concurrent chemotherapy (standard fluoropyrimidine-based regimen)",[15],[29],{"name":30,"affiliation":5,"role":31},"Peter Ihnát, prof., MD, PhD, MBA","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Jiří Hynčica","CONTACT","0042059737","2587","jiri.hyncica@fno.cz",[40,58,69,82],{"facility":41,"status":42,"city":43,"state":24,"zip":44,"country":45,"countryCode":24,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University Hospital Olomouc","RECRUITING","Olomouc","779 00","Czechia",{"type":47,"coordinates":48},"Point",[49,50],17.25175,49.59552,{"lat":50,"lon":49},[53,57],{"name":54,"role":35,"phone":55,"phoneExt":24,"email":56},"Petr Špička, MD, PhD","00420588442415","petr.spicka@fnol.cz",{"name":54,"role":31,"phone":24,"phoneExt":24,"email":24},{"facility":59,"status":42,"city":43,"state":24,"zip":24,"country":45,"countryCode":24,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"Palacky University Olomouc, Faculty of Medicine",{"type":47,"coordinates":61},[49,50],{"lat":50,"lon":49},[64,68],{"name":65,"role":35,"phone":66,"phoneExt":24,"email":67},"Josef Srovnal, M.D., Ph.D., Assist. Prof.","00420585632137","josef.srovnal@upol.cz",{"name":65,"role":31,"phone":24,"phoneExt":24,"email":24},{"facility":5,"status":42,"city":70,"state":24,"zip":71,"country":45,"countryCode":24,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Ostrava","70852",{"type":47,"coordinates":73},[74,75],18.28204,49.83465,{"lat":75,"lon":74},[78,81],{"name":30,"role":35,"phone":36,"phoneExt":79,"email":80},"5701","peter.ihnat@fno.cz",{"name":30,"role":31,"phone":24,"phoneExt":24,"email":24},{"facility":83,"status":42,"city":70,"state":24,"zip":84,"country":45,"countryCode":24,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"Municipal Hospital Ostrava - Fifejdy","728 80",{"type":47,"coordinates":86},[74,75],{"lat":75,"lon":74},[89],{"name":90,"role":35,"phone":91,"phoneExt":24,"email":92},"Branislav Šnajder, MD","00420596192480","chirurgie@mnof.cz",{"type":94,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[96,98,99],{"name":97,"class":6},"Palacky University",{"name":41,"class":6},{"name":100,"class":6},"Municipal Hospital Ostrava","100607904","rectal-cancer-ctc-trial-100607904",false,"NCT07194616","Rectal Cancer CTC Trial","Impact of Neoadjuvant Chemoradiotherapy Versus Surgery Alone on Circulating Tumor Cells in Patients With Stage II-III Rectal Cancer and Negative Circumferential Resection Margin: a Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed rectal adenocarcinoma within 12 cm from anal verge\n* Stage II (cT3-4 N0 M0) or stage III (cT1-4 N1-2, M0)\n* Negative circumferential resection margin on staging MRI\n* ASA physical status I-III\n* Signed informed consent\n\nExclusion Criteria:\n\n* Tumor infiltration beyond fascia recti propria on MRI\n* Metastatic disease (stage IV)\n* Recurrent rectal cancer\n* Other concurrent malignancies\n* Emergency surgery required\n* Contraindication to surgery under general anesthesia","ALL","18 Years",{"count":111,"type":112},120,"ESTIMATED","INTERVENTIONAL",[115],"NA","This prospective, multi-centre, randomised clinical trial aims to compare the effect of neoadjuvant chemoradiotherapy versus primary surgery on circulating tumor cells (CTCs) in patients with stage II-III rectal cancer without circumferential resection mar-gin involvement. CTCs are considered a promising biomarker for disease dissemination and treatment response. Patients will be randomized to either primary surgical resection with total mesorectal excision or long-course neoadjuvant chemoradiotherapy followed by surgery. Serial blood samples will be collected at predefined time points to assess the presence and dynamics of CTCs. Secondary endpoints include perioperative morbidity and mortality, local recurrence rate, disease-free survival, and overall survival. The results of this study may provide new insights into the prognostic role of CTCs and contribute to optimising treatment strategies for rectal cancer.",[118],"Rectal Cancer Patients",[120,121,122,123,124,125],"circulating tumor cells","liquid biopsy","neoadjuvant chemoradiotherapy","prognostic biomarkers","rectal cancer","surgical resection","2025-09-18",{"date":128,"type":129},"2025-09-26","ACTUAL",{"date":131,"type":129},"2025-04-01",{"date":133,"type":112},"2028-03-30",{"name":5,"class":6},4]